Activation of hepatocyte growth factor/activin A/follistatin system during hemodialysis: Role of heparin

Kidney International

Volumn 64, Issue 6, 2003, Pages 2229-2237

  Borawski, Jacek ^a   Naumnik, Beata ^a   Myśliwiec, Michał ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Activin A; Enoxaparin; Follistatin; Hemodialysis; Heparin; Hepatocyte growth factor

Indexed keywords

ACTIVIN A; ANTICOAGULANT AGENT; ENOXAPARIN; FOLLISTATIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; SCATTER FACTOR;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING DISORDER; BLOOD ANALYSIS; BLOOD CLOTTING DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; DRUG INFUSION; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; IMMUNOASSAY; KIDNEY DISEASE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 0344083394     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00307.x     Document Type: Article

References (40)

1. ZARNEGAR R, MICHALOPOULOS GK: The many faces of hepatocyte growth factor: From hepatopoiesis to hematopoiesis. J Cell Biol 129:1177-1180, 1995
2. FUNAKOSHI H, NAKAMURA T: Hepatocyte growth factor: From diagnosis to clinical applications. Clin Chim Acta 327:1-23, 2003
3. MAESHIMA A, ZHANG Y-Q, FURUKAWA M, et al: Hepatocyte growth factor induces branching tubulogenesis in MDCK cells by modulating the activin-follistatin system. Kidney Int 58:1511-1522, 2000
4. NIIMI S, HYUGA M, KAZAMA H, et al: Activins A, AB, and B inhibit hepatocyte growth factor synthesis by MRC-5 human lung fibroblasts. Biol Pharm Bull 25:1405-1408, 2002
5. CHEN YG, LUI HM, LIN SL, et al: Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp Biol Med 227:75-78, 2002
6. MOLLOY CJ, TAYLOR DS, PAWLOWSKI JE: Novel cardiovascular actions of the activins. J Endocrinol 161:179-185, 1999
7. PHILLIPS DJ, JONES KL, SCHEERLINCK JY, et al: Evidence for activin A and follistatin involvement in the systemic inflammatory response. Mol Cell Endocrinol 180:155-162, 2001
8. SHAV-TAL Y, ZIPORI D: The role of activin A in regulation of hemopoiesis. Stem Cells 20:493-500, 2002
9. SAKAI R, ETO Y: Involvement of activin in the regulation of bone metabolism. Mol Cell Endocrinol 180:183-188, 2001
10. SUGIMURA K, KIM T, GOTO T, et al: Serum hepatocyte growth factor levels in patients with chronic renal failure. Nephron 70:324-328, 1995
11. RAMPINO T, LIBETTA C, DE SIMONE W, et al: Hemodialysis stimulates hepatocyte growth factor release. Kidney Int 53:1382-1388, 1998
12. MALATINO LS, MALLAMACI M, BENEDETTO FA, et al: Hepatocyte growth factor predicts survival and relates to inflammation and intima media thickness in end-stage renal disease. Am J Kidney Dis 36:945-952, 2000
13. BORAWSKI J, PAWLAK K, NAUMNIK B, MYSLIWIEC M: Relations between oxidative stress, hepatocyte growth factor, and liver disease in hemodialysis patients. Ren Fail 24:825-837, 2002
14. MALATINO LS CATALIOTTI A, BENEDETTO FA, et al: Hepatocyte growth factor and left ventricular geometry in end-stage renal disease. Hypertension 41:88-92, 2003
15. BORAWSKI J, MYSLIWIEC M: Serum hepatocyte growth factor is associated with viral hepatitis, cardiovascular disease, erythropoietin treatment, and type of heparin in haemodialysis patients. Nephrol Dial Transplant 17:637-644, 2002
16. RAMPINO T, ARBUSTINI E, GREGORINI M, et al: Hemodialysis prevents liver disease caused by hepatitis C virus: Role of hepatocyte growth factor. Kidney Int 56:2286-2291, 1999
17. SHIOZAKI M, SAKAI R, TABUCHI M, et al: The existence of activin A/erythroid differentiation factor and its inhibitor in human serum: Comparison of normal and chronic renal failure sera. Biochem Biophys Res Commun 183:273-279, 1992
18. SAKAMOTO Y, SHINTANI Y, HARADA K, et al: Determination of free follistatin levels in sera of normal subjects and patients with various diseases. Eur J Endocrinol 135:345-351, 1995
19. ZIONCHECK TF, RICHARDSON L, LIU J, et al: Sulfated oligosaccharides promote hepatocyte growth factor association and govern its mitogenic activity. J Biol Chem 270:16871-16878, 1995
20. KATO Y, LIU KX, NAKAMURA T, SUGIYAMA Y: Heparin-hepatocyte growth factor complex with low plasma clearance and retained hepatocyte proliferating activity. Hepatology 20:417-424, 1994
21. LIU KX, KATO Y, TERASAKI T, AOKI S, et al: Existence of two non-linear elimination mechanisms for hepatocyte growth factor in rats. Am J Physiol 273:891-897, 1997
22. MATSUMOTO K, TAJIMA H, OKAZAKI H, NAKAMURA T: Heparin as an inducer of hepatocyte growth factor. J Biochem 114:820-826, 1993
23. MATSUMOTO K, NAKAMURA T: Heparin functionates as a hepatotrophic factor by inducing production of hepatocyte growth factor. Biochem Biophys Res Commun 227:455-461, 1996
24. PHILLIPS DJ, JONES KL, MCGAW DJ, et al: Release of activin and follistatin during cardiovascular procedures is largely due to heparin administration. J Clin Endocrinol Metab 85:2411-2415, 2000
25. SALTISSI D, MORGAN C, WESTHUYZEN J, HEALY H: Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation. Nephrol Dial Transplant 14:2698-2703, 1999
26. OUSEPH R, WARD RA: Anticoagulation for intermittent hemodialysis. Semin Dial 13:181-187, 2000
27. SEIDEL C, HJORTH-HANSEN H, BENDZ B, et al: Hepatocyte growth factor in serum after injection of unfractionated and low molecular weight heparin in healthy individuals. Br J Haematol 105: 641-647, 1999
28. SALBACH PB, BRÜCKMANN M, TUROVETS O, et al: Heparin-mediated selective release of hepatocyte growth factor in humans. Br J Clin Pharmacol 50:221-226, 2000
29. HASHIMOTO O, NAKAMURA T, SHOJI H, et al: A novel role of follistatin, an activin-binding protein, in the inhibition of activin action in rat pituitary cells. Endocytotic degradation of activin and its acceleration by follistatin associated with cell-surface heparan sulphate. J Biol Chem 272:13835-13842, 1997
30. SUMITOMO S, INOUYE S, LIU X-J, et al: The heparin binding site of follistatin is involved in its interaction with activin. Biochem Biophys Res Commun 208:1-9, 1995
31. SANDSET PM, BENDZ B, HANSEN JB. Physiological function of tissue factor pathway inhibitor and interaction with heparins. Haemostasis 30(Suppl 2):48-56, 2000
32. KOZAKI K, AKISHITA M, ETO M, et al: Role of activin-A and follistatin in foam cell formation of THP-1 macrophages. Arterioscler Thromb Vasc Biol 17:2389-2394, 1997
33. ENGELSE MA NEELE JM, VAN ACHTERBERG TEA, et al: Human activin-A is expressed in the atherosclerotic lesion and promotes the contractile phenotype of smooth muscle cells. Circ Res 85:931-939, 1999
34. SCHWALL RE, ROBBINS K, JARDIEU P, et al: Activin induces cell death in hepatocytes in vivo and in vitro. Hepatology 18:347-356, 1993
35. OKADA M, MATSUMORI A, ONO K, et al: Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis. Biochem Biophys Res Commun 255:80-87, 1999
36. NAKAO T, ARII S, KAIDO A, et al: Heparin accelerates liver regeneration following portal branch ligation in normal and cirrhotic rats with increased plasma hepatocyte growth factor. J Hepatol 37:87-92, 2002
37. KINOSHITA M, MIYAMOTO T, OHASHI N, et al: Thrombosis increases circulatory hepatocyte growth factor by degranulation of mast cells. Circulation 106:3133-3138, 2002
38. HEESCHEN C, DIMMELER S, HAMM CW, et al: Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation 107:524-530, 2003
39. KALANTAR-ZADEH K, BLOCK G, HUMPHREYS MH, KOPPLE JD: Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 63:793-808, 2003
40. GRIFFIOEN AW, MOLEMA G: Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 52:237-268, 2000